Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAs.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31073154.
- Also identified by DOI 10.1038/s41467-019-09985-2 and PMC identifier 6509140.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The CRISPR-Cas9 system provides the ability to edit, repress, activate, or mark any gene (or DNA element) by pairing of a programmable single guide RNA (sgRNA) with a complementary sequence on the DNA target. Here we present a new method for small-molecule control of CRISPR-Cas9 function through insertion of RNA aptamers into the sgRNA. We show that CRISPR-Cas9-based gene repression (CRISPRi) can be either activated or deactivated in a dose-dependent fashion over a >10-fold dynamic range in response to two different small-molecule ligands. Since our system acts directly on each target-specific sgRNA, it enables new applications that require differential and opposing temporal control of multiple genes.
Medical subject headings
- Aptamers, Nucleotide
- CRISPR-Associated Protein 9
- CRISPR-Cas Systems
- Gene Editing
- RNA, Guide, CRISPR-Cas Systems